Clene Narrows Losses but Shares Plunge Post-Earnings

Clene reported Q4 2025 earnings on March 17, 2026, with results showing a narrowed net loss but a significant revenue decline. The company’s shares surged 49.15% month-to-date, contrasting with a post-earnings strategy that yielded a -46.63% CAGR. Analysts expect continued losses but maintain a “Moderate Buy” consensus.

Revenue

Clene’s total revenue fell 15.4% year-over-year to $77,000 in Q4 2025, down from $91,000 in Q4 2024. The decline reflects ongoing challenges in scaling core operations, despite strategic cost-cutting measures.

Earnings/Net Income

The company narrowed its quarterly loss to $0.85 per share in Q4 2025, a 49.2% improvement from $1.67 per share in Q4 2024. Net losses also decreased to -$9.23 million, a 31.9% reduction from -$13.55 million. While these improvements highlight progress in cost management, the company has sustained losses for six consecutive years, underscoring structural financial challenges. The narrowing loss suggests cautious optimism, but continued negative EPS remains a critical concern for investors.

Price Action

Clene’s stock gained 0.49% in the latest trading day, 12.68% over the past week, and 49.15% month-to-date as of March 17, 2026.

Post-Earnings Price Action Review

The strategy of buying Clene shares after its Q4 2025 earnings report, which included a revenue decline, and holding for 30 days resulted in a CAGR of -46.63% and an excess return of -140.99%. With a maximum drawdown of 98.27% and a Sharpe ratio of -0.43, the approach exposed investors to severe risk and failed to generate positive returns.

CEO Commentary

Business Performance: Clene’s CEO acknowledged a 15.4% revenue decline but highlighted a 31.9% reduction in net losses, crediting operational efficiency initiatives. Strategic Priorities: The CEO emphasized accelerating R&D in its lead therapeutic candidate and expanding partnerships to unlock growth. Leadership Outlook: While expressing confidence in long-term potential, the CEO admitted “significant headwinds” remain, urging patience as the company transitions toward profitability.

Guidance

The CEO reiterated a focus on R&D investment and cost discipline, with no explicit forward-looking financial targets provided. However, the company remains committed to reducing losses through operational optimization.

Additional News

1. Institutional Investments: Jane Street Group and Ensign Peak Advisors increased stakes in Clene, with the latter boosting holdings by 668.6% in Q4 2025.

2. Insider Sales: Major shareholder Chidozie Ugwumba sold 15,284 shares in January 2026, marking a 2.63% reduction in his position.

3. Analyst Upgrades: UBS Group reiterated a “Buy” rating, citing long-term therapeutic pipeline potential despite near-term losses.